Aerogen Founder & CEO
A serial entrepreneur in a technology and innovation focused career spanning over 30 years, John has held executive-level positions in R&D, Operations, Sales, and General Management in both the SME and MNC environment. During this period he has been a founder or co-founder of several ‘Blue Ocean’ technology start-ups, the last three of these in the life-science sector.
John has led the company from a start-up in 1997 through a US merger, NASDAQ IPO, trade sale and return to a privately held company by MBO in 2008. Today Aerogen is recognised as a pioneer and the global leader, in ICU ventilator/hospital-based aerosol drug delivery. Its award-winning products are employed in over 75 countries throughout the world, helping to provide life critical interventions from the emergency department through to the NICU. Aerogen’s proprietary technology permits proteins, peptides, suspensions and solutions to be nebulized, paving the way for targeted drug delivery to the lung.
Under John’s Leadership Aerogen has achieved circa 30% CAGR since 2008 and in recognition of its export success, Aerogen was awarded the prestigious European Business Award Ruban d’Honneur in 2011 and again in 2016, when John was also named the European Entrepreneur of the Year. As a leader within the Irish life-science sector, Aerogen was named both The Irish Med-Tech Company of the Year and The Irish Exporter of the Year. The Company has received the highest award granted by the US respiratory community, the American Association of Respiratory Care, the Zenith Award, for ‘providing products and services that enable respiratory care physicians and therapists to achieve clinical excellence’.
A Chartered Engineer, John is recognized as a technology innovator and is credited with over a dozen commercialized international patents in products ranging from robotics to life-support ventilation. He holds an MBA from Oxford Brookes University and as an Adjunct Professor at the National University of Ireland, Galway (NUIG), he guest lectures on his core business interests of Innovation Strategies and Technology Entrepreneurship.
He is a founder faculty member of the NUIG Bio-Innovate program (run in conjunction with Stanford University Bio-Design), an incubator unit that promotes entrepreneurial start-ups in medical technologies where he has actively mentored several early-stage companies. In 2016, in recognition of his contribution to the development of the Irish Medical Device sector, John was conferred with an Honorary Doctorate by the National University of Ireland, Galway.
John is a Board member of Kedalion Therapeutics Inc. a pioneering ophthalmic drug delivery company based in San Francisco. He is a former member of the Board of the Irish Med-Tech Association and The Irish Research Council for Science, Engineering, and Technology and has represented Ireland as an industry expert in the European Competitive Council in Brussels.
John is a very active social entrepreneur in his local community where he long-term member of his Community Development Association and a founder member of The Connemara Greenway Alliance. An ardent supporter of International charities such as World Vision and Their Life’s Matter’ he continues to lead significant fundraising initiatives for irrigation / agricultural, healthcare, and local enterprise creation in the developing world.
Ethan Jung Ryun Park is a Director at Temasek, a global investment firm headquartered in Singapore. Ethan is based in London and leads the firm’s healthcare investment efforts in EMEA. Previously, he worked at SK Corporation in Seoul, Korea. Ethan received a BA from Tufts University, where he was a member of Phi Beta Kappa and graduated magna cum laude, and an MS from the London School of Economics and Political Science. He has also received an international diploma from the Institut d’Etudes Politiques de Paris (Sciences Po).
Ethan currently serves on the board of Alvogen, and has served on the boards of BenevolentAI and Celltrion Healthcare.